Key result
The new turbidimetric digoxin immunoassay minimized false-positive digoxin measurements from endogenous digoxin-like immunoreactive factors compared to FPIA (1 vs 21 false positives).
Why the study?
Does the new turbidimetric digoxin immunoassay minimize interference from endogenous digoxin-like immunoreactive factors compared to FPIA and CLIA?
Population
50 serum specimens from individuals never exposed to digoxin.
Comparison
Turbidimetric digoxin immunoassay on the ADVIA… vs Fluorescence polarization immunoassay and…
Design
Other
Authors
Loading...
Does not support changing digoxin assays yet; leaves open outcome validation in clinical cohorts.
Cross-Sectional (n=50)
Does the new turbidimetric digoxin immunoassay minimize interference from endogenous digoxin-like immunoreactive factors compared to FPIA and CLIA?
The new turbidimetric digoxin immunoassay on the ADVIA 1650 analyzer significantly reduces false-positive digoxin measurements caused by endogenous digoxin-like immunoreactive factors compared to older assays like FPIA.
Datta et al. (2004) conducted a cross-sectional in Conditions increasing serum DLIF concentrations (n=50). Turbidimetric digoxin immunoassay vs. Fluorescence polarization immunoassay (FPIA) and chemiluminescent immunoassay (CLIA) was evaluated on Apparent digoxin concentrations (false positives due to DLIF). The new turbidimetric digoxin immunoassay minimized false-positive digoxin measurements from endogenous digoxin-like immunoreactive factors compared to FPIA (1 vs 21 false positives).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: